1. Qiagen Acquires Eppendorf's Reagent Business; Firms to Align Techs (from Jan. 5)
2. As 454 Enabled Mammoth Project, Next-Generation Sequencers Will Drive Paleogenomics (from Jan. 3)
3. Predictive Diagnostics Closes Doors as Nasdaq Delists LSBC (from Jan. 3)
4. Third Wave CEO Gets New Salary; FDA Names Acting Tox Director; Exiqon Announces Head of US Operations; and Others (from Jan. 4)
5. Without Roche, Epigenomics Completes Validation Study for Prostate Cancer Dx (from Jan. 4)